Just when we think the story of hydroxychloroquine is over, today Lancet issued a retraction of its earlier study that claimed people being treated with the antimalarial drugs hydroxychloroquine and chloroquine are at a higher risk of death and irregular heart rhythms than those not receiving it.
The retraction stems from another story we reported late last month after Surgisphere Corp was caught falsifying data for which the Lancet study was based on. In statement The Lancet said: “Today, three of the authors of the paper, “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”, have retracted their study.”
Below is the complete statement
Today, three of the authors of the paper, “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis”, have retracted their study. They were unable to complete an independent audit of the data underpinning their analysis. As a result, they have concluded that they “can no longer vouch for the veracity of the primary data sources.” The Lancet takes issues of scientific integrity extremely seriously, and there are many outstanding questions about Surgisphere and the data that were allegedly included in this study. Following guidelines from the Committee on Publication Ethics (COPE) and International Committee of Medical Journal Editors (ICMJE), institutional reviews of Surgisphere’s research collaborations are urgently needed.
The retraction notice is published today, June 4, 2020. The article will be updated to reflect this retraction shortly.